Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
HPB (Oxford) ; 23(11): 1656-1665, 2021 11.
Article in English | MEDLINE | ID: mdl-34544628

ABSTRACT

INTRODUCTION: The SARS-CoV-2 pandemic presented healthcare providers with an extreme challenge to provide cancer services. The impact upon the diagnostic and treatment capacity to treat pancreatic cancer is unclear. This study aimed to identify national variation in treatment pathways during the pandemic. METHODS: A survey was distributed to all United Kingdom pancreatic specialist centres, to assess diagnostic, therapeutic and interventional services availability, and alterations in treatment pathways. A repeating methodology enabled assessment over time as the pandemic evolved. RESULTS: Responses were received from all 29 centres. Over the first six weeks of the pandemic, less than a quarter of centres had normal availability of diagnostic pathways and a fifth of centres had no capacity whatsoever to undertake surgery. As the pandemic progressed services have gradually improved though most centres remain constrained to some degree. One third of centres changed their standard resectable pathway from surgery-first to neoadjuvant chemotherapy. Elderly patients, and those with COPD were less likely to be offered treatment during the pandemic. CONCLUSION: The COVID-19 pandemic has affected the capacity of the NHS to provide diagnostic and staging investigations for pancreatic cancer. The impact of revised treatment pathways has yet to be realised.


Subject(s)
COVID-19 , Pancreatic Neoplasms , Aged , Humans , Pancreatic Neoplasms/epidemiology , Pancreatic Neoplasms/therapy , Pandemics , SARS-CoV-2 , United Kingdom/epidemiology
2.
Am J Pathol ; 186(4): 748-60, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26835538

ABSTRACT

Alcohol-induced liver damage is a major burden for most societies, and murine studies can provide a means to better understand its pathogenesis and test new therapies. However, there are many models reported with widely differing phenotypes, not all of which fully regenerate the spectrum of human disease. Thus, it is important to understand the implications of these variations to efficiently model human disease. This review critically appraises key articles in the field, detailing the spectrum of liver damage seen in different models, and how they relate to the phenotype of disease seen in patients. A range of different methods of alcohol administration have been studied, ranging from ad libitum consumption of alcohol and water to modified diets (eg, Lieber deCarli liquid diet). Other feeding regimens have taken more invasive routes using intragastric feeding tubes to infuse alcohol directly into the stomach. Notably, models using wild-type mice generally produce a milder phenotype of liver damage than those using genetically modified mice, with the exception of the chronic binge-feeding model. We recommend panels of tests for consideration to standardize end points for the evaluation of the severity of liver damage-key for comparison of models of injury, testing of new therapies, and subsequent translation of findings into clinical practice.


Subject(s)
Ethanol/pharmacology , Fatty Liver, Alcoholic/pathology , Hepatitis, Alcoholic/diagnosis , Hepatitis, Alcoholic/pathology , Liver Diseases, Alcoholic/pathology , Acute Disease , Animals , Disease Models, Animal , Fatty Liver, Alcoholic/diagnosis , Humans , Liver Diseases, Alcoholic/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...